Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6773232 | 0.80 | PTGS2 (0.43) | HSP90AA1HSP90AB1PTGS2CRBNPTGS1 | |
| SCHEMBL19953122 | 0.78 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1CYP11B1CYP11B2FLT3 | |
| SCHEMBL6180979 | 0.78 | PTGS2 (0.63) | PTGS2PTGS1 | |
| SCHEMBL6294248 | 0.78 | PTGS2 (0.63) | PTGS2PTGS1 | |
| SCHEMBL10773460 | 0.77 | FLT3 (0.55) | HSP90AA1HSP90AB1CYP11B1CYP11B2FLT3 | |
| SCHEMBL25611833 | 0.77 | FLT3 (0.47) | HSP90AA1HSP90AB1CYP11B1CYP11B2FLT3 | |
| SCHEMBL6294332 | 0.77 | MAPK14 (0.54) | HSP90AA1HSP90AB1PTGS2CYP11B1CYP11B2 | |
| SCHEMBL15208735 | 0.76 | IDO1 (0.36) | PTGS2CRBNPTGS1 | |
| SCHEMBL6289834 | 0.75 | PTGS2 (0.63) | PTGS2PTGS1 | |
| SCHEMBL5698464 | 0.73 | MAPK14 (0.44) | PTGS2PTGS1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1281709-B1 | NOVEL HETEROCYCLIC COMPOUNDS WITH ANTI-INFLAMMATORY ACTIVITY | URIACH Y COMPANIA S A J (ES) | 2005-02-16 | — | — | EP | disclosed |
| US-6838476-B1 | Cyclooxygenase inhibitors; anticancer agents | J. URIACH & CIA, SA (ES) | 2005-01-04 | — | — | US | disclosed |
| EP-1122243-B1 | NOVEL IMIDAZOLES WITH ANTI-INFLAMMATORY ACTIVITY | URIACH Y COMPANIA S A J (ES) | 2004-09-08 | — | — | EP | disclosed |
| US-20030114456-A1 | Novel heterocylic compounds with anti-inflamatory activity | J. URIACH & CIA, S.A. (ES) | 2003-06-19 | — | — | US | disclosed |
| EP-1281709-A1 | NOVEL HETEROCYCLIC COMPOUNDS WITH ANTI-INFLAMMATORY ACTIVITY | J. URIACH & CIA. S.A. (ES) | 2003-02-05 | — | — | EP | disclosed |
| EP-1122243-A1 | NOVEL IMIDAZOLES WITH ANTI-INFLAMMATORY ACTIVITY | J. URIACH & CIA. S.A. (ES) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114456-A1 | Novel heterocylic compounds with anti-inflamatory activity | IL1B, IL1A, NFKBIA | HSP90AA1 418/4885HSP90AB1 475/4885PTGS2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.